Colgate Palmolive CO Form 4 insider transactions

Director Lorrie M Norrington acquired 258 shares of Colgate-Palmolive common stock at $91.99 per share on April 1, 2025, through a deferred compensation plan.

John P. Bilbrey, a director of Colgate-Palmolive, acquired 231 shares of common stock at a price of $91.99 on April 1, 2025, through a deferred compensation plan.

Sally Massey, Chief Human Resources Officer of Colgate-Palmolive, sold 8,000 shares of common stock at an average price of $92.019 on February 25, 2025.

Colgate-Palmolive's CEO, Noel Wallace, reported the vesting of performance-based restricted stock units and the subsequent withholding of shares for tax obligations.

Panagiotis Tsourapas, Group President, Europe & Developing Markets at Colgate-Palmolive, reports acquisition and disposal of company stock related to vesting of performance-based restricted stock units and associated tax obligations.

Chief Financial Officer of Colgate-Palmolive, Stanley Sutula III, reports acquisition and disposal of company stock related to vesting of performance-based restricted stock units and tax obligations.

Prabha Parameswaran, Group President of Growth & Strategy at Colgate-Palmolive, reports the vesting of performance-based restricted stock units and related tax withholding.

Sally Massey, Chief Human Resources Officer at Colgate-Palmolive, reports the vesting of restricted stock units and related tax withholding.

Gregory Malcolm, EVP and Controller at Colgate-Palmolive, reports acquisition of shares through vesting of restricted stock units and disposition of shares for tax liability.

Jennifer Daniels, CLO and Secretary of Colgate-Palmolive, reports acquisition of shares through vesting of restricted stock units and disposition of shares for tax liability.

Director John P. Bilbrey acquired 228 shares of Colgate-Palmolive common stock at $93.18 per share on January 2, 2025, through a deferred compensation plan.

Director Brian Newman acquired 201 shares of Colgate-Palmolive stock at $93.18 per share on January 2, 2025, increasing his direct holdings to 2,388 shares.

Director Lorrie M. Norrington acquired 281 shares of Colgate-Palmolive common stock at $93.18 per share on January 2, 2025, according to a Form 4 filing.

Panagiotis Tsourapas, a Group President at Colgate-Palmolive, reported a transaction involving the withholding of 168 shares for tax obligations.

Colgate-Palmolive's Chief Financial Officer, Stanley J. Sutula III, sold 252 shares of common stock to cover tax liabilities related to previously granted restricted stock units.

Colgate-Palmolive's CEO, Noel Wallace, disposed of 954 shares of common stock to cover Medicare and income tax liabilities related to previously granted restricted stock units.

A Colgate-Palmolive executive, Prabha Parameswaran, sold 229 shares of common stock to cover tax liabilities related to previously granted restricted stock units.

Gregory Malcolm, EVP and Controller at Colgate-Palmolive, sold 42 shares of common stock to cover tax liabilities related to restricted stock units.

Jennifer Daniels, CLO and Secretary at Colgate-Palmolive, reported a transaction involving the withholding of 168 common stock shares for tax liabilities.

A Form 4 filing reveals that Colgate-Palmolive's EVP and Controller, Gregory Malcolm, sold 1,054 shares and gifted 1,387 shares of company stock.

Colgate-Palmolive's CEO, Noel Wallace, sold 33,333 shares of common stock at $95 per share on November 22, 2024, as part of a pre-arranged trading plan.

Chief Financial Officer of Colgate-Palmolive, Stanley Sutula III, executed stock options and sold shares to cover the exercise price and related taxes.

Panagiotis Tsourapas, a Group President at Colgate-Palmolive, sold 20,032 shares of common stock at an average price of $93.3012 on November 4, 2024.

Stanley Sutula III, CFO of Colgate-Palmolive, exercised stock options and sold 50,000 shares of common stock on November 1, 2024.

Director Brian Newman reports acquiring and disposing of Colgate-Palmolive common stock on October 1, 2024.

Director Lisa Edwards acquired 89 shares of Colgate-Palmolive common stock through a deferred compensation plan on October 1, 2024.

Director John P. Bilbrey acquired 201 shares of Colgate-Palmolive common stock at $105.24 per share on October 1, 2024, according to a recent SEC filing.

Director Lorrie M. Norrington increased her holdings in Colgate-Palmolive through a deferred compensation plan, acquiring 249 shares at $105.24 each.

Colgate-Palmolive CEO Noel Wallace reports acquisition of restricted stock units and stock options, as well as the disposal of shares to cover tax liabilities.

Panagiotis Tsourapas, a Group President at Colgate-Palmolive, reported the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover tax liabilities.